Still, a recent meta-analysis and metaregression study of all available randomised trials investigating different DCB in the femoropopliteal segment has identified only a weak adverse relationship between incidence of CLI and reduction of TLR rates by paclitaxel-coated balloons—on the other hand, paclitaxel dose was the strongest, highly significant predictor of the expected biological effect size of DCB treatment. 16 Hence, the authors consider the present results generalisable for different treatment indications for femoropopliteal disease.
← all excerpts
Economic analysis of endovascular drug-eluting treatments for femoropopliteal artery disease in the UK.
1
—
—